- Author: Kathy Keatley Garvey
In research led by postdoctoral researcher Zuodong Zhang, a team of 16 scientists discovered a key mechanism by which dietary omega-3 fatty acids (fish oils) could reduce the tumor growth and spread of cancer, a disease that kills some 580,000 Americans a year.
The research is published today (April 3) in the Proceedings of the National Academy of Sciences (PNAS). They discovered cytochrome P450 epoxygenase metabolites of omega-3 fatty acid DHA or epoxy docosapentaenoic acids (EDPs) block blood supply to the tumor and thus inhibit tumor growth and metastasis.
The natural EDPs were further stabilized by a drug called a soluble epoxide hydrolase inhibitor which is already under development to control pain and hypertension.
“Many human studies have shown that omega-3 fatty acids reduce the risks of cancers, but the mechanism is poorly understood,” said Zhang, a postdoctoral researcher who focuses his research on lipid mediators on angiogenesis, tumor growth and metastasis. “Our study provides a novel mechanism by which these omega-3 lipids inhibit cancer.”
“We demonstrated that EDPs have very potent anti-cancer and anti-metastatic effects,” Zhang said. “Current anti-cancer drugs that block angiogenesis (the formation of new blood vessels to fuel tumor progression) can cause serious side effects such as hypertension. By blocking angiogenesis by a new mechanism and by widening blood vessels, EDPs could block tumor growth with reduced side effects in cancer patients.”
The studies, conducted on mice, also suggest that a combination of omega-3 diet and some anti-cancer drugs such as sorafenib, “could not only be efficacious to treat cancers but reduce potential side effects,” said Zhang, who received his doctorate in food science from the University of Wisconsin-Madison.
“Thus the effects of the soluble epoxide hydrolase inhibitors have opposite effects depending on whether the background lipid mediators are omega 3 or omega 6,” Hammock said. “Assuming that humans are mice (the study involved mice), the prediction is that with some cancer drugs--particularly the ones like sorafenib and regorafenib that are potent epoxide hydrolase inhibitors as well as anti-angiogenic agents--these could be more effective with a high omega 3 and low omega 6 background.”
“This is an exciting step towards our full appreciation of the impact of bioactive products from the DHA metabolome,” said Charles Serhan of Harvard Medical School, an expert on omega-3 autacoids and inflammation who is the Simon Gelman Professor of Anesthesia, Periopterative and Pain Medicine, Harvard Medical School. “This (UC Davis) contribution places metabolic conversion of omega-3 DHA to epoxy DHA products pivotal in vascular mechanisms key in cancer and vascular biology. It will be exciting to watch these important findings translated to humans for new evidence based treatments for angiogenesis, tumor growth and cancer metastasis.”
Said cardiologist Jonathan Lindner of the Oregon Health & Science University: “New drug strategies for fighting cancer could emerge from knowledge of how the body uses nutrition to promote health. Diet has been shown to influence susceptibility to many types of cancer, and also to influence rate of tumor progression and response to chemotherapy. This information has been leveraged to make reasonable recommendations on diet in patients with cancer. Perhaps more importantly, by uncovering how diet influences tumor development and growth, it may be possible to develop new drugs that work through the same beneficial pathways.”
“The study by Zhang and colleagues has uncovered a previously unrecognized anti-cancer effect of omega-3 fatty acids which are an important lipid component of diets that have been developed to prevent heart disease and cancer,” Lindner said. “The authors have demonstrated that metabolites of these lipids can act to suppress the growth of new blood vessels that are necessary to feed tumor growth. By shutting off the tumor’s blood supply, these compounds can act to dramatically slow tumor growth and prevent metastasis. The results from this suggest that new drug strategies for fighting cancer could emerge from knowledge of how the body uses nutrition to promote health.”
Read more about the research on the UC Davis Department of Entomology website and see photos of some of the co-authors.
- Author: Kathy Keatley Garvey
It promises to be a lively discussion.
UC Davis entomologist Bruce Hammock, distinguished professor of entomology, will speak on “From Butterflies to Blood Pressure and Beyond: Is It Possible to Get a Drug to the Clinic with a University’s Help?” at a Science Café session set Wednesday, April 3 at 5:30 p.m. in Crepeville, 330 3rd St., Davis.
The session, open to the public and billed as “a conversation with Professor Bruce Hammock,” will be hosted by the UC Davis Division of Math and Physical Sciences. Co-sponsor is the Department of Chemistry. Professor Jared T. Shaw will introduce Hammock.
Said Hammock: “The science is how basic research on insects has led to a drug for blocking hypertension and neuropathic pain. The general discussion is on the difficulties of translating basic science paid for by the taxpayer, into a technology that can actually help the taxpayer.”
Hammock, a member of the UC Davis Department of Entomology faculty since 1980, holds a joint appointment with the UC Davis Comprehensive Cancer Research Center, and directs the campuswide Superfund Research Program, National Institutes of Health Biotechnology Training Program, and the National Institute of Environmental Health Sciences (NIEHS) Combined Analytical Laboratory.
He is a fellow of the Entomological Society of America, a member of the prestigious National Academy of Sciences, and the recipient of the 2001 UC Davis Faculty Research Lecture Award and the 2008 Distinguished Teaching Award for Graduate and Professional Teaching.
- Author: Kathy Keatley Garvey
Take entomologist Bruce Hammock, distinguished professor of entomology at the University of California, Davis. Forty years ago, while studying insect development, he discovered a group of anti-inflammatory compounds called sEH (soluble epoxide hydrolases) inhibitors.
In 2005 he began collaborating with cardiologist and cell biologist Nipavan Chiamvimonvat of the School of Medicine’s Division of Cardiovascular Medicine.
Fast forward to today.
Today an 11-scientist team from the Chiamvimonvat and Hammock labs published groundbreaking research in the Proceedings of National Academic of Sciences that shows a new treatment may help prevent and reduce cardiac fibrosis, a common occurrence in patients after a heart attack.
The research utilized a treatment involving a compound synthesized by Sing Lee and Sung Hee Hwang in the Hammock lab. The scientists determined the molecular mechanisms underlying the beneficial effects of soluble epoxide hydrolase (sEH) inhibitors in a heart attack.
“Our study (using rodents) provides evidence for a possible new therapeutic strategy to reduce cardiac fibrosis and improve cardiac function after a heart attack,” Chiamvimonvat told us.
Every year some 935,000 U.S. residents have a heart attack, according to the Centers for Disease Control and Prevention. Heart disease kills about 600,000 a year, accounting for one in every four deaths in the nation.
The research, “New Mechanistic Insights into the Beneficial Effects of Soluble Epoxide Hydrolase Inhibitors in the Prevention of Cardiac Fibrosis,” is “really important in terms of understanding a unique pathway which may be targeted to reduce fibrosis and adverse cardiac remodeling,” Chiamvimonvat said.
The lead authors of the research paper are Padmini Sirish and Ning Li of the Chiamvimonvat lab, and Jun-Yan Liu of the Hammock lab. In addition, other researchers involved in the project are Kin Sing Stephen Lee, and Sung Hee Hwang of the Hammock lab; Hong Qiu, Cuifen Zhao, and Siu Mei Ma of the Chiamvimonvat lab, and López, who developed the methods to quantitate the fibrotic cells using flow cytometry.
Chiamvimonvat and Hammock have filed patents with the University of California for sEH inhibitors and cardiac hypertrophy therapy and organ fibrosis.
A multi-talented scientist and administrator, Hammock holds a joint appointment with the UC Davis Comprehensive Cancer Research Center, and directs the campuswide Superfund Research Program, National Institutes of Health Biotechnology Training Program, and the National Institute of Environmental Health Sciences (NIEHS) Combined Analytical Laboratory. He is a fellow of the Entomological Society of America, a member of the prestigious National Academy of Sciences, and the recipient of the 2001 UC Davis Faculty Research Lecture Award and the 2008 Distinguished Teaching Award for Graduate and Professional Teaching.
Read more about Hammock's research activities on his lab website. More information on the Hammock/Chiamvimonvat research appears on the Department of Entomology's website.
- Author: Kathy Keatley Garvey
Hoover, who received her doctorate in entomology from UC Davis in 1997, will discuss “Co-Evolution in a Host Baculovirus System” from noon to 1 p.m. in 366 Briggs Hall.
She will be in California in conjunction with her trip to Ventura to participate in the Gordon Research Conference, an international forum for the presentation and discussion of frontier research in the biological, chemical, and physical sciences, and their related technologies.
“The gypsy moth has a long co-evolutionary history with its host specific baculovirus, Lymantria dispar NPV,” Hoover said. “As a result, the gypsy moth has evolved counter-defenses against the virus, while in return the virus has strategies for increasing its own fitness at the expense of the host. For example, anti-viral defenses include apoptosis of infected cells (despite viral inhibitor of apoptosis genes), while the virus manipulates host behavior to enhance transmission to new hosts, which is an example of the extended phenotype.”
While a grad student at UC Davis, Hoover studied with major professors Bruce Hammock and Sean Duffey (1943-1997). After a one-year postdoctoral position at UC Berkeley, she joined the faculty of the Penn State University Department of Entomology in 1998.
Her research program at Penn State focuses on invasive species, including development of trapping techniques for the Asian longhorned beetle; gut microbial symbionts of the Asian longhorned beetle and hemlock woolly adelgid; functions of key viral genes in transmission of the gypsy moth baculovirus and anti-viral defenses; and biological control of hemlock woolly adelgid.
Hoover is the lead author of the highly acclaimed research, “A Gene for an Extended Phenotype,” published Sept. 9, 2011 in Science. It was selected for the Faculty of 1000 (F1000), which places her work in its library of the top 2 percent of published articles in biology and medicine.
- Author: Kathy Keatley Garvey
You'll never guess what Bruce Hammock did on Dec. 18.
First, a bit about Bruce Dupree Hammock. He's a distinguished professor of entomology at the University of California, Davis; he holds a joint appointment with the UC Davis Comprehensive Cancer Center; and he directs the campuswide Superfund Research Program, National Institutes of Health Biotechnology Training Program, and the National Institute of Environmental Health Sciences (NIEHS) Combined Analytical Laboratory.
He’s an athlete who loves rock climbing and white-water rafting and hosts the annual Bruce Hammock Water Balloon Battle in front of Briggs Hall for his students, researchers and colleagues.
So, what did he do on Dec. 18? He embarked upon an acting career.
His first role?
A corpse.
Hammock grew a beard, donned his father's old ragged World War II clothes and worn-out shoes, and practiced looking like a corpse. He then drove to a secluded place in the high desert, near Mojave, to participate in the production on Dec. 18. (The details are top secret.)
“It was very interesting,” Hammock. “But my, the producers work hard. We were on the set at 5:30 a.m. We worked until dark, in weather well below freezing, with high winds blowing sand. The professional actors and actresses put in amazing performances under quite adverse conditions."
“They’re a very professional and fun group. I had never realized the complexity of filming a movie. I hope they pull off their vision.”
Hammock, who is a fellow of the Entomological Society of America, a member of the prestigious National Academy of Sciences, and the recipient of the 2001 UC Davis Faculty Research Lecture Award and the 2008 Distinguished Teaching Award for Graduate and Professional Teaching, doesn’t think his acting career is so established that he’ll be nominated for an Academy Award.
At least not soon.
And the beard? Will he shave?
Yes. The movie role is over.
His colleague, chemical ecologist Walter Leal, joked: “Just before he left, Bruce mentioned he was dressing to shoot a movie. I didn’t notice any difference; I thought he was taking off for another scientific meeting.”